Patents Assigned to Cognition Therapeutics, Inc.
-
Publication number: 20240409509Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.Type: ApplicationFiled: January 16, 2024Publication date: December 12, 2024Applicant: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
-
Publication number: 20240165077Abstract: The present disclosure relates to methods of treating neurological diseases, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein. The present disclosure relates to the methods of treating Parkinson's disease and Dementia with Lew Bodies, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.Type: ApplicationFiled: March 17, 2022Publication date: May 23, 2024Applicant: Cognition Therapeutics, Inc.Inventors: Anthony CAGGIANO, Susan M. CATALANO, Mary HAMBY, Nicholas IZZO, Gary C. LOOK, Gilbert M. RISHTON
-
Patent number: 11981636Abstract: The present disclosure relates to novel compounds of Formula I wherein each of Ra, Rb, Rd and Re is independently H; Rc is selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF3, SO2CH3, and morpholino, R1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH?C(CH3)2; and R2 is specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.Type: GrantFiled: November 29, 2021Date of Patent: May 14, 2024Assignee: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. Rishton, Gary C. Look, Susan M. Catalano
-
Publication number: 20240150288Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: ApplicationFiled: April 27, 2023Publication date: May 9, 2024Applicant: Cognition Therapeutics, Inc.Inventors: Gilbert M. RISHTON, Susan M. CATALANO, Gary C. LOOK
-
Publication number: 20240009168Abstract: The present disclosure relates to methods of treating dry age-related macular degeneration (dry AMD), comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.Type: ApplicationFiled: December 10, 2021Publication date: January 11, 2024Applicant: Cognition Therapeutics, Inc.Inventors: Anthony CAGGIANO, Susan CATALANO, Mary HAMBY, Nicholas IZZO, Gary LOOK, Gilbert RISHTON
-
Patent number: 11691947Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: GrantFiled: February 6, 2020Date of Patent: July 4, 2023Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
-
Publication number: 20230098944Abstract: The present disclosure relates to methods of decreasing amyloid ? monomers and methods of treating cognitive decline in a subject, wherein the treatment results in an increase in amyloid ? oligomers and a reduction in cognitive decline. The present disclosure relates to treating cognitive decline, wherein target engagement can be measured in the clinic after treating.Type: ApplicationFiled: February 12, 2021Publication date: March 30, 2023Applicant: Cognition Therapeutics, Inc.Inventors: Susan CATALANO, Nicholas IZZO
-
Publication number: 20220356153Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.Type: ApplicationFiled: November 29, 2021Publication date: November 10, 2022Applicant: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
-
Patent number: 11214540Abstract: The present disclosure relates to novel compounds, and pharmaceutical compositions thereof, useful for treating for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.Type: GrantFiled: May 15, 2018Date of Patent: January 4, 2022Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Gary C. Look, Susan M. Catalano
-
Publication number: 20210009517Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: ApplicationFiled: February 6, 2020Publication date: January 14, 2021Applicant: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
-
Publication number: 20200338045Abstract: The present invention is directed to methods of treating Alzheimer's disease. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's disease as well as methods of determining the Alzheimer's disease status of a subject.Type: ApplicationFiled: November 1, 2018Publication date: October 29, 2020Applicant: COGNITION THERAPEUTICS, INC.Inventors: Susan M. CATALANO, Nicholas J. IZZO
-
Publication number: 20200299234Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.Type: ApplicationFiled: May 15, 2018Publication date: September 24, 2020Applicant: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
-
Patent number: 10611728Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: GrantFiled: December 21, 2018Date of Patent: April 7, 2020Assignee: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
-
Publication number: 20190210966Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: ApplicationFiled: December 21, 2018Publication date: July 11, 2019Applicant: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
-
Patent number: 10207991Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: GrantFiled: September 11, 2017Date of Patent: February 19, 2019Assignee: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. Rishton, Susan M. Catalano, Gary C. Look
-
Patent number: 9815770Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.Type: GrantFiled: October 16, 2015Date of Patent: November 14, 2017Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan Catalano
-
Patent number: 9796672Abstract: Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.Type: GrantFiled: January 30, 2015Date of Patent: October 24, 2017Assignee: COGNITION THERAPEUTICS, INC.Inventors: Gilbert Rishton, Susan M. Catalano, Gary C. Look
-
Publication number: 20170197977Abstract: This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.Type: ApplicationFiled: August 27, 2012Publication date: July 13, 2017Applicant: COGNITION THERAPEUTICS, INC.Inventors: Susan M. Catalano, Gilbert Rishton, Nicholas J. Izzo
-
Patent number: 9499462Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.Type: GrantFiled: February 1, 2012Date of Patent: November 22, 2016Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan Catalano
-
Patent number: 9365491Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.Type: GrantFiled: June 2, 2014Date of Patent: June 14, 2016Assignee: COGNITION THERAPEUTICS, INC.Inventors: Gilbert M. Rishton, Susan Catalano